Systems and methods for mechanogenetic functional ultrasound imaging
US-12172037-B2 · Dec 24, 2024 · US
Compositions and methods for treating antiphospholipid syndrome
US8993518B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993518-B2 |
| Application number | US-201113881284-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 31, 2011 |
| Priority date | Nov 5, 2010 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target β2GPI in β2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the invention include two ligand-binding A1 modules, e.g., from ApoER2, connected by a flexible linker.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating antiphospholipid syndrome in a subject in need thereof comprising administering a composition comprising a polypeptide, wherein said polypeptide comprises a first low density lipoprotein (LDL) receptor-type A (LA) module, a second LA module, and a linker that joins said first LA module to said second LA module; and wherein said first LA module comprises a first A1 domain comprising an amino acid sequence with 85% or more sequence ident…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
- C07K14/705Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8993518B2 cover?
- The invention features compositions and methods of using a dimeric inhibitor, e.g., A1-A1, to selectively target β2GPI in β2GPI/antibody complexes. The compositions can be administered to subjects (e.g., a mammal, such as a human) having or likely to develop APS, or one or more symptoms of APS, in order to treat or inhibit the disease or treat or reduce its symptoms. The inhibitors of the inven…
- Who is the assignee on this patent?
- Beglova Natalia, Beth Israel Hospital
- What technology area does this patent fall under?
- Primary CPC classification C07K14/705. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).